Drug information provided by: Merative, Micromedex®
Pemetrexed injection is used in combination with pembrolizumab and platinum cancer medicines as the first treatment of metastatic (cancer that has spread) non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK gene mutations. It is also used together with cisplatin as the first treatment of advanced or metastatic, non-squamous NSCLC.
Pemetrexed injection is also used as maintenance treatment of advanced or metastatic NSCLC that has not progressed after a previous 4-cycle treatment with platinum cancer medicines. It is also used to treat metastatic non-squamous NSCLC that has come back after a previous chemotherapy.
Pemetrexed injection is also used together with cisplatin as the first treatment of malignant pleural mesothelioma (cancer that affects the inside lining of the lungs and chest wall) that cannot be removed by surgery. Pemetrexed belongs to the group of medicines called antineoplastics.
This medicine is given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: May 01, 2023
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?